May 20, 2020
Volpara Solutions Signs Collaboration Agreement with Ambry Genetics
May 19, 2020
ScreenPoint Medical Announces Key Senior Leadership Hire - Vice President Of Sales for the US
May 19, 2020
Hoag is First in Nation to Test Innovative Antibody Brain Cancer Drug
May 18, 2020
Exciting Diagnostic Innovations Alter the Healthcare Landscape
May 14, 2020
Breastcancer.org Study Finds 4 in 10 Breast Cancer Patients Have Used Cannabis to Treat a Variety of Symptoms
May 11, 2020
AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patients
May 07, 2020
Breast Cancer Screening Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Test Type ; End User, and Geography
May 06, 2020
Midstate Radiology Associates, LLC Offers High-Risk Cancer Screening Program
May 05, 2020
Theresa's Research Foundation Launches PAVE
Apr 28, 2020
Geisinger study of blood test for cancer shows promising results
Apr 28, 2020
IceCure's Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India
Apr 27, 2020
I-SPY2 TRIAL Demonstrates Significant Improvement in pCR with Durvalumab and Olaparib with Paclitaxel, (Compared to Chemotherapy Alone) in Women with Stage II/III High-Risk, HER2-Negative Breast Cancer, in HR+ and TNBC Subsets
Apr 23, 2020
Concure Oncology Names Scott Armstrong as New Chief Executive Officer
Apr 23, 2020
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
Apr 23, 2020
New Early Breast Cancer Drug Available Now In Singapore
Apr 22, 2020
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement With MTS Medical Technology
Apr 22, 2020
IntraOp® Announces First Patient Enrolled in Cosmopolitan Trial for Breast Cancer
Apr 16, 2020
Thinking about Breast Cancer and Breast Reconstruction During the Coronavirus Pandemic
Apr 16, 2020
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
Apr 16, 2020
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment